A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Idelalisib (Primary) ; Ruxolitinib
- Indications Myelofibrosis; Thrombocytosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 30 Nov 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 14 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.